XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders’ Equity
3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Stockholders’ Equity

13. Stockholders’ Equity

The following tables present changes in stockholders’ equity for the three-month periods ended March 31, 2023 and 2022 (in thousands, except share data):

 

 

 

 

 

 

 

Additional

 

 

Accumulated Other

 

 

 

 

 

Total

 

 

Common

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2022

 

87,103,007

 

 

$

9

 

 

$

2,420,223

 

 

$

(7,461

)

 

$

(1,177,187

)

 

$

1,235,584

 

Issuance of common stock through
   at-the-market offerings, net of
   issuance costs of $
62

 

35,349

 

 

 

-

 

 

 

1,466

 

 

 

-

 

 

 

 

 

 

1,466

 

Contingent consideration paid to Rewrite holders

 

567,045

 

 

 

-

 

 

 

24,126

 

 

 

-

 

 

 

 

 

 

24,126

 

Exercise of stock options

 

48,353

 

 

 

-

 

 

 

755

 

 

 

-

 

 

 

 

 

 

755

 

Vesting of restricted stock units

 

342,025

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

-

 

Equity-based compensation

 

-

 

 

 

-

 

 

 

27,255

 

 

 

-

 

 

 

 

 

 

27,255

 

Other comprehensive loss - unrealized gain on marketable securities

 

-

 

 

 

-

 

 

 

-

 

 

 

2,989

 

 

 

 

 

 

2,989

 

Other comprehensive loss - equity method investment

 

-

 

 

 

-

 

 

 

-

 

 

 

1,794

 

 

 

 

 

 

1,794

 

Net loss

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

(103,126

)

 

 

(103,126

)

Balance at March 31, 2023

 

88,095,779

 

 

$

9

 

$

2,473,825

 

$

(2,678

)

 

$

(1,280,313

)

 

$

1,190,843

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated Other

 

 

 

 

 

Total

 

 

Common

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Stockholders’

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Equity

 

Balance at December 31, 2021

 

74,485,883

 

 

$

7

 

 

$

1,745,870

 

 

$

(2,632

)

 

$

(703,001

)

 

$

1,040,244

 

Issuance of common stock through
   at-the-market offerings, net of
   issuance costs of $
164

 

579,788

 

 

 

1

 

 

 

38,885

 

 

 

-

 

 

 

-

 

 

 

38,886

 

Exercise of stock options

 

503,830

 

 

 

-

 

 

 

8,435

 

 

 

-

 

 

 

-

 

 

 

8,435

 

Vesting of restricted stock units

 

54,666

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Equity-based compensation

 

-

 

 

 

-

 

 

 

18,491

 

 

 

-

 

 

 

-

 

 

 

18,491

 

Other comprehensive loss - unrealized loss on marketable securities

 

-

 

 

 

-

 

 

 

-

 

 

 

(5,128

)

 

 

-

 

 

 

(5,128

)

Other comprehensive loss - equity method investment

 

-

 

 

 

-

 

 

 

-

 

 

 

(302

)

 

 

-

 

 

 

(302

)

Net loss

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(146,872

)

 

 

(146,872

)

Balance at March 31, 2022

 

75,624,167

 

 

$

8

 

$

1,811,681

 

$

(8,062

)

 

$

(849,873

)

 

$

953,754

 

At-the-Market Offering Programs

In August 2019, the Company entered into an Open Market Sale Agreement (the “2019 Sale Agreement”) with Jefferies LLC (“Jefferies”), under which Jefferies was able to offer and sell, from time to time in “at-the-market” offerings, common stock having aggregate gross proceeds of up to $150.0 million. The Company agreed to pay Jefferies cash commissions of 3.0% of the gross proceeds of sales of common stock under the 2019 Sale Agreement.

During the first quarter of 2022, the Company issued 579,788 shares of its common stock, in a series of sales, at an average price of $69.43 per share, in accordance with the 2019 Sale Agreement for aggregate net proceeds of $38.9 million, after payment of cash commissions to Jefferies and approximately $0.2 million related to legal, accounting and other fees in connection with the sales. The 2019 Sale Agreement expired in the third quarter of 2022.

In March 2022, the Company entered into an Open Market Sale Agreement (the “2022 Sale Agreement”) with Jefferies, under which Jefferies will be able to offer and sell, from time to time in “at-the-market” offerings, shares of the Company’s common stock having aggregate gross proceeds of up to $400.0 million. The Company agreed to pay Jefferies cash commissions of 3.0% of the gross proceeds of sales of common stock under the 2022 Sale Agreement.

During the year ended December 31, 2022, the Company issued 3,395,339 shares of its common stock, in a series of sales, at an average price of $57.43 per share, in accordance with the 2022 Sale Agreement for aggregate net proceeds of $189.0 million, after payment of cash commissions to Jefferies and approximately $0.1 million related to legal, accounting and other fees in connection with the sales. During the quarter ended March 31, 2023, the Company issued 35,349 shares of its common stock, in a series of sales, at an average price of $44.58 per share, in accordance with the 2022 Sale Agreement for aggregate net proceeds

of $1.5 million, after payment of cash commissions to Jefferies and approximately $0.1 million related to legal, accounting and other fees in connection with the sales. As of March 31, 2023, $203.4 million in shares of common stock remain eligible for sale under the 2022 Sale Agreement.